Effie Pournara

791 total citations
36 papers, 483 citations indexed

About

Effie Pournara is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Effie Pournara has authored 36 papers receiving a total of 483 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Rheumatology, 14 papers in Immunology and 12 papers in Hematology. Recurrent topics in Effie Pournara's work include Spondyloarthritis Studies and Treatments (24 papers), Rheumatoid Arthritis Research and Therapies (17 papers) and Psoriasis: Treatment and Pathogenesis (14 papers). Effie Pournara is often cited by papers focused on Spondyloarthritis Studies and Treatments (24 papers), Rheumatoid Arthritis Research and Therapies (17 papers) and Psoriasis: Treatment and Pathogenesis (14 papers). Effie Pournara collaborates with scholars based in Switzerland, Germany and United Kingdom. Effie Pournara's co-authors include Bente Klarlund Pedersen, Xenofon Baraliakos, Michael Rissler, Laura C. Coates, Barbara Schulz, Laure Gossec, Sławomir Jeka, Chiara Perella, Antonio Mera and Salvatore D’Angelo and has published in prestigious journals such as PLoS ONE, Annals of the Rheumatic Diseases and Journal of the American Academy of Dermatology.

In The Last Decade

Effie Pournara

36 papers receiving 471 citations

Peers

Countries citing papers authored by Effie Pournara

Since Specialization

Citations

This map shows the geographic impact of Effie Pournara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Effie Pournara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Effie Pournara more than expected).

Fields of papers citing papers by Effie Pournara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Effie Pournara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Effie Pournara. The network helps show where Effie Pournara may publish in the future.

Co-authorship network of co-authors of Effie Pournara

This figure shows the co-authorship network connecting the top 25 collaborators of Effie Pournara. A scholar is included among the top collaborators of Effie Pournara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Effie Pournara. Effie Pournara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Magnetic resonance imaging characteristics in patients with psoriatic arthritis and axial manifestations from the MAXIMISE cohort 2023 ·Lara D. Veeken ·Xenofon Baraliakos, Effie Pournara, Laura C. Coates, Victoria Navarro‐Compán, Ricardo Blanco, Eamonn O’Brien, Barbara Schulz, Robert Landewé	6
2	Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis 2023 ·Rheumatology and Therapy ·Alexis Ogdie, Dafna D. Gladman, Laura C. Coates, Effie Pournara, (unknown), Philip J. Mease	1
3	Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review 2023 ·Journal of Dermatological Treatment ·Paolo Gisondi, David Simón, Ivette Alarcón, Effie Pournara, L. Puig	1
4	Patient clusters identified by machine learning from a pooled analysis of the clinical development programme of secukinumab in psoriatic arthritis, ankylosing spondylitis and psoriatic arthritis with axial manifestations 2023 ·Clinical and Experimental Rheumatology ·Xenofon Baraliakos, Effie Pournara, Laura C. Coates, Philip J. Mease, Samad Jahandideh, Dafna D. Gladman	3
5	Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial 2023 ·The Lancet Rheumatology ·Nils Venhoff, Wolfgang Schmidt, Raoul Bergner, Jürgen Rech, L. Unger, Hans‐Peter Tony, Stephanie Finzel, (unknown), David M. Kofler, Stefan M. Weiner, Peter Lamprecht, Hendrik Schulze‐Koops, Christine App, Effie Pournara, Meryl H. Mendelson, Christian Sieder, (unknown), Jens Thiel	33
6	Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial 2022 ·RMD Open ·Xenofon Baraliakos, Effie Pournara, Laure Gossec, Philip J. Mease, (unknown), Eamonn O’Brien, Barbara Schulz, Helena Marzo‐Ortega, Laura C. Coates	3
7	POS1053 LONG-TERM RETENTION, EFFECTIVENESS AND SAFETY OF SECUKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OR ANKYLOSING SPONDYLITIS: RESULTS FROM THE OBSERVATIONAL SERENA STUDY 2022 ·Annals of the Rheumatic Diseases ·Uta Kiltz, PP Sfikakis, (unknown), (unknown), (unknown), (unknown), Éric Lespessailles, N Maiden, Karl Gaffney, Daniel Peterlik, (unknown), Effie Pournara, (unknown)	1
8	Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study 2022 ·Dermatology and Therapy ·Peter Foley, Tsen‐Fang Tsai, Karl Rodins, (unknown), Alfred Ammoury, (unknown), (unknown), Susanne Crowe, (unknown), Effie Pournara, (unknown), Yu‐Huei Huang	13
9	Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab 2022 ·Rheumatology and Therapy ·Uta Kiltz, Petros P. Sfikakis, Karl Gaffney, Andreas Bounas, Nicola Gullick, Éric Lespessailles, (unknown), Rasho Rashkov, Barbara Schulz, Effie Pournara, (unknown)	8
10	Magnetic resonance imaging characteristics in patients with spondyloarthritis and clinical diagnosis of heel enthesitis: post hoc analysis from the phase 3 ACHILLES trial 2022 ·Arthritis Research & Therapy ·Xenofon Baraliakos, Philipp Sewerin, Eugenio de Miguel, Effie Pournara, (unknown), (unknown), Claudia Jentzsch, A. Wiedon, Frank Behrens, (unknown)	6
11	Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis 2021 ·RMD Open ·Effie Pournara, Matthías Kormáksson, Peter Nash, Christopher T. Ritchlin, Bruce Kirkham, Gregory Ligozio, Luminita Pricop, Alexis Ogdie, Laura C. Coates, Georg Schett, Iain B. McInnes	20
12	25851 Efficacy of secukinumab in managing axial manifestations and nail psoriasis in patients with psoriatic arthritis: Results from the MAXIMISE trial 2021 ·Journal of the American Academy of Dermatology ·Alice B. Gottlieb, Xenofon Baraliakos, Laura C. Coates, Effie Pournara, Michael Rissler, (unknown), Chiara Perella, Kristian Reich, Dafna D. Gladman, Maher Aassi	1
13	Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial 2021 ·Therapeutic Advances in Musculoskeletal Disease ·Denis Poddubnyy, Effie Pournara, (unknown), Asta Baranauskaitė, (unknown), (unknown), Barbara Schulz, Michael Rissler, Chiara Perella, Helena Marzo‐Ortega	5
14	A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis 2021 ·Rheumatology and Therapy ·Irene van der Horst‐Bruinsma, Corinne Miceli‐Richard, Jürgen Braun, Helena Marzo‐Ortega, Karel Pavelká, Alan Kivitz, Atul Deodhar, Weibin Bao, Brian Porter, Effie Pournara	10
15	Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial 2020 ·Annals of the Rheumatic Diseases ·Xenofon Baraliakos, Laure Gossec, Effie Pournara, Sławomir Jeka, Antonio Mera, Salvatore D’Angelo, Barbara Schulz, Michael Rissler, (unknown), Chiara Perella, Laura C. Coates	110
16	Achilles tendon enthesitis evaluated by MRI assessments in patients with axial spondyloarthritis and psoriatic arthritis: a report of the methodology of the ACHILLES trial 2020 ·BMC Musculoskeletal Disorders ·Xenofon Baraliakos, Philipp Sewerin, Eugenio de Miguel, Effie Pournara, (unknown), A. Wiedon, Frank Behrens	12
17	Is GH dosing optimal in female patients with adult‐onset GH deficiency? An analysis from the NordiNet^® International Outcome Study 2017 ·Clinical Endocrinology ·Charlotte Höybye, Matthias M. Weber, Effie Pournara, Bente Klarlund Pedersen, Beverly M. K. Biller	5
18	Early growth hormone treatment start in childhood growth hormone deficiency improves near adult height: analysis from NordiNet® International Outcome Study 2017 ·European Journal of Endocrinology ·Michel Polak, Joanne Blair, Primož Kotnik, Effie Pournara, Bente Klarlund Pedersen, Tilman Rohrer	49
19	Short Stature: Comparison of WHO and National Growth Standards/References for Height 2016 ·PLoS ONE ·Henrik Thybo Christesen, Bente Klarlund Pedersen, Effie Pournara, Isabelle Petit, Pétur Benedikt Júlíusson	42
20	Is safety of childhood growth hormone therapy related to dose? Data from a large observational study 2016 ·European Journal of Endocrinology ·Lars Sävendahl, Effie Pournara, Bente Klarlund Pedersen, Oliver Blankenstein	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact